Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Vaccinations01:51

Vaccinations

Overview
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Bacterial Gastroenteritis01:18

Bacterial Gastroenteritis

Bacterial gastroenteritis, characterized by diarrhea, abdominal cramps, and vomiting, is often caused by ingestion of contaminated food or water and is frequently associated with pathogenic Escherichia coli strains. These microbes exploit two principal mechanisms to inflict disease.Shiga toxin–producing E. coli, also referred to as STEC—notably O157:H7—release Shiga toxins that target ribosomes, blocking protein synthesis. The B subunit of the toxin binds the host glycolipid receptor...
Diphtheria01:28

Diphtheria

Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A feasibility study of chromatographic methods with mass spectrometry, flame ionization detector (FID), and micro electron capture detector (μECD) for laboratory adoption of organic gunshot residue analysis at trace levels.

Journal of forensic sciences·2026
Same author

A glycan-based adjuvant expands the breadth and duration of protection of mRNA-based vaccines.

Nature immunology·2026
Same author

Introducing QUIT-the Quality and Uncertainty Indicator Triage tool: 10 questions to help veterinary professionals more confidently triage treatment study reports.

Journal of the American Veterinary Medical Association·2026
Same author

Advances in Clostridioides difficile research: Insights from the 8th International C. difficile symposium (ICDS 2024).

Anaerobe·2026
Same author

<i>Listeria monocytogenes</i> septicemia in foals: A case series (1986 to 2024).

The Canadian veterinary journal = La revue veterinaire canadienne·2026
Same author

CAT-GxD: Centralized access to gene expression datasets.

Anaerobe·2025
Same journal

Projected health and economic impact of PCV20 vaccination in UK children: a dynamic transmission model.

Expert review of vaccines·2026
Same journal

Evaluating the societal value of adult respiratory vaccination in Sweden: a benefit-cost analysis.

Expert review of vaccines·2026
Same journal

Evaluating the socioeconomic value of adult respiratory immunization in Spain: a benefit-cost analysis.

Expert review of vaccines·2026
Same journal

Whole cell and acellular pertussis vaccines - rethinking the evidence.

Expert review of vaccines·2026
Same journal

Modeling the potential public health and economic impact and cost-effectiveness of vaccination strategies using an adapted COVID-19 vaccine in the Dominican Republic.

Expert review of vaccines·2026
Same journal

Narrative shielding and prebunking: a synergistic strategy against vaccine hesitancy in pediatrics.

Expert review of vaccines·2026
See all related articles

Related Experiment Video

Updated: May 12, 2026

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
09:12

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection

Published on: June 15, 2018

Carbohydrate-based Clostridium difficile vaccines.

Mario A Monteiro1, Zuchao Ma, Lisa Bertolo

  • 1University of Guelph, Guelph, ON, N1G 2W1, Canada. monteiro@uoguelph.ca

Expert Review of Vaccines
|April 9, 2013
PubMed
Summary
This summary is machine-generated.

A new vaccine targeting Clostridium difficile (C. difficile) shows promise. Researchers developed vaccines based on phosphorylated polysaccharides, particularly PSII, to disrupt bacterial colonization and persistence, offering a potential solution for C. difficile infections.

More Related Videos

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

Related Experiment Videos

Last Updated: May 12, 2026

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
09:12

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection

Published on: June 15, 2018

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

Area of Science:

  • Microbiology
  • Immunology
  • Vaccine Development

Background:

  • Clostridium difficile causes thousands of deaths annually.
  • A vaccine is needed to disrupt bacterial colonization and persistence in carriers and convalescent patients.
  • C. difficile expresses three phosphorylated polysaccharides: PSI, PSII, and PSIII.

Purpose of the Study:

  • To develop vaccines based on C. difficile phosphorylated polysaccharides, focusing on PSII as a common antigen.
  • To evaluate the design and immunogenicity of these polysaccharide-based vaccines.

Main Methods:

  • Structural exploration of C. difficile to identify potential vaccine targets.
  • Design and synthesis of vaccines using raw polysaccharides and their conjugates.
  • Immunogenicity studies in various animal models and analysis of human/equine antibody responses.

Main Results:

  • Anti-PSII antibodies were successfully raised in farm animals, mice, and hamsters.
  • Humans and horses naturally carry anti-PSII IgA and IgG antibodies, respectively.
  • Phosphate is a critical immunogenic epitope, and vaccine-induced antibodies recognize PSII on the C. difficile surface.

Conclusions:

  • Vaccines based on C. difficile phosphorylated polysaccharides, especially PSII, are immunogenic.
  • The phosphate moiety is essential for the immunogenicity of PSII.
  • These findings support the development of a C. difficile vaccine targeting PSII to combat infections.